Natural history of hepatitis C: Its impact on clinical management

Hepatology

Volumn 31, Issue 4, 2000, Pages 1014-1018

  Di Bisceglie, Adrian M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL;

EID: 0034069745     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/he.2000.5762     Document Type: Article

References (25)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. HEPATOLOGY 1990;12:671-675.
2. Di Bisceglie AM, Goodman ZG, Ishal KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. HEPATOLOGY 1991;14:969-974.
3. Colombo M, Kuo G, Choo QL, Donate MF, Del Ninno E, Tommasini MA, Dioguardi N, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008.
4. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;ii:1004-1006.
5. Tong MJ, El-Farra N, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
6. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-1911.
7. Kenny-Walsh E and the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
8. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
9. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
10. Sobesky R, Mathurin P, Charlotte F, Mousalli J, Olivi M, Vidaud M, Ratziu V, et al. Modeling the impact of Interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 1999;116:378-386.
11. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, et al. Prevalence and outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.
12. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
13. Smith EC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. HEPATOLOGY 1998;27:1695-1699.
14. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. HEPATOLOGY 1997;26(Suppl):34S-38S.
15. Miller WJ, Baron RL, Dodd GD, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994;193:645-650.
16. International working party. Terminology of nodular hepatocellular lesions. HEPATOLOGY 1995:22:983-993.
17. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, Leandro G, Servida E, Podda M. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1998;108:812-816.
18. Theise ND. Cirrhosis and hepatocellular neoplasia: more like cousins than like parent and child (Editorial). Gastroenterology 1996;111:526-528.
19. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, Mitamura K, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351:1773-1777.
20. Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M, Lang D, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Eng J Med 1997;336:1855-1859.
21. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-181.
22. International Interferon Hepatocellular Carcinoma Study Group, Brunetto M, Oliven F, Koehler M, Zahm F, Bonino F Effect of Interferon on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-1539.
23. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, et al. Relation of Interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-99.
24. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. HEPATOLOGY 1998;27:1394-1402.
25. Bonkovsky H, Di Bisceglie AM, Dienstag J, Everson G, Lindsay K, Gretch D, Hoefs J, et al. A randomized, controlled trial of long-term antiviral therapy in patients with chronic hepatitis C and advanced hepatic fibrosis who have previously not responded to interferon therapy: design of the "hepatitis antiviral long-term treatment to prevent cirrhosis (HALT-C) trial." Gastroenterology 2000 (in press) (abstract).